{"id":"hydronidone-placebo-group","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a placebo group assignment in a clinical trial, Hydronidone contains no active pharmaceutical ingredient and produces no direct therapeutic effect. It serves as a control comparator to assess the efficacy and safety of an active investigational drug by isolating the true pharmacological benefit from placebo response.","oneSentence":"Hydronidone is a placebo control agent with no active pharmacological mechanism.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:48:06.011Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07412236","phase":"PHASE3","title":"A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B.","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2026-01-30","conditions":"Liver Fibrosis, Liver Fibrosis in Chronic Hepatitis B","enrollment":1208},{"nctId":"NCT07263152","phase":"PHASE1","title":"QTc Assessment in a Single-Dose Study of Hydronidone Capsules","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2025-12-01","conditions":"Hepatic Fibrosis","enrollment":48},{"nctId":"NCT07262346","phase":"PHASE1","title":"The Phase Ⅰd Clinical Trial of Hydronidone Capsules","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2025-12-05","conditions":"Liver Fibrosis","enrollment":138},{"nctId":"NCT05905172","phase":"PHASE3","title":"Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis","status":"RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2023-08-12","conditions":"Liver Fibrosis","enrollment":248},{"nctId":"NCT05115942","phase":"PHASE3","title":"Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial.","status":"COMPLETED","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2021-12-30","conditions":"Liver Fibrosis","enrollment":248},{"nctId":"NCT02499562","phase":"PHASE2","title":"A Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic Hepatitis","status":"COMPLETED","sponsor":"Shanghai Genomics, Inc.","startDate":"2015-06-25","conditions":"Hepatitis B, Chronic","enrollment":168}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Hydronidone (Placebo Group)","genericName":"Hydronidone (Placebo Group)","companyName":"Beijing Continent Pharmaceutical Co, Ltd.","companyId":"beijing-continent-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}